Gland Pharma [GLAND] vs GlaxoSmithKline [GLAXO] Detailed Stock Comparison

Gland Pharma Ltd.

NSE
Loading...

GlaxoSmithKline Pharmaceuticals Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Gland Pharma Ltd. wins in 10 metrics, GlaxoSmithKline Pharmaceuticals Ltd. wins in 10 metrics, with 0 ties. Both stocks appear equally matched on key metrics.

View Metrics Details

Vital Metrics Comparison

Metric Gland Pharma Ltd. GlaxoSmithKline Pharmaceuticals Ltd. Better
P/E Ratio (TTM) 34.86 41.55 Gland Pharma Ltd.
Price-to-Book Ratio 3.09 24.80 Gland Pharma Ltd.
Debt-to-Equity Ratio 3.16 2.09 GlaxoSmithKline Pharmaceuticals Ltd.
PEG Ratio 0.58 2.44 Gland Pharma Ltd.
EV/EBITDA 18.80 31.46 Gland Pharma Ltd.
Profit Margin (TTM) 13.86% 26.86% GlaxoSmithKline Pharmaceuticals Ltd.
Operating Margin (TTM) 19.30% 33.71% GlaxoSmithKline Pharmaceuticals Ltd.
EBITDA Margin (TTM) 19.30% 33.71% GlaxoSmithKline Pharmaceuticals Ltd.
Return on Equity 7.63% 47.54% GlaxoSmithKline Pharmaceuticals Ltd.
Return on Assets (TTM) 6.22% 22.58% GlaxoSmithKline Pharmaceuticals Ltd.
Free Cash Flow (TTM) $5.21B $12.65B GlaxoSmithKline Pharmaceuticals Ltd.
Dividend Yield 1.95% 1.65% Gland Pharma Ltd.
1-Year Return 33.88% -35.63% Gland Pharma Ltd.
Price-to-Sales Ratio (TTM) 4.84 11.14 Gland Pharma Ltd.
Enterprise Value $266.81B $397.44B GlaxoSmithKline Pharmaceuticals Ltd.
EV/Revenue Ratio 4.37 10.46 Gland Pharma Ltd.
Gross Profit Margin (TTM) 65.99% 65.06% Gland Pharma Ltd.
Revenue per Share (TTM) $371 $224 Gland Pharma Ltd.
Earnings per Share (Diluted) $51.50 $60.16 GlaxoSmithKline Pharmaceuticals Ltd.
Beta (Stock Volatility) 0.41 0.10 GlaxoSmithKline Pharmaceuticals Ltd.

Gland Pharma Ltd. vs GlaxoSmithKline Pharmaceuticals Ltd. Stock Performance Analysis

Loading Price Chart...

GLAND
GLAXO

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Gland Pharma Ltd.-2.31%-1.82%18.29%37.34%32.35%28.86%
GlaxoSmithKline Pharmaceuticals Ltd.-0.31%-3.19%-13.28%-11.99%-17.96%-13.88%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Gland Pharma Ltd.33.88%124.19%-26.40%24.33%24.33%24.33%
GlaxoSmithKline Pharmaceuticals Ltd.-35.63%50.14%45.44%-39.87%-9.78%324.98%

Performance & Financial Health Analysis: Gland Pharma Ltd. vs GlaxoSmithKline Pharmaceuticals Ltd.

MetricGLANDGLAXO
Market Information
Market Cap i₹295.80B₹422.67B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i98,02642,008
90 Day Avg. Volume i91,78251,960
Last Close₹2,210.00₹2,115.00
52 Week Range₹1,573.60 - ₹2,396.00₹2,088.10 - ₹3,500.00
% from 52W High-7.76%-39.57%
All-Time High₹4,350.00 (Aug 09, 2021)₹3,872.00 (Mar 28, 2016)
% from All-Time High-49.20%-45.38%
Growth Metrics
Quarterly Revenue Growth0.23%0.10%
Quarterly Earnings Growth0.28%0.29%
Financial Health
Profit Margin (TTM) i0.14%0.27%
Operating Margin (TTM) i0.19%0.34%
Return on Equity (TTM) i0.08%0.48%
Debt to Equity (MRQ) i3.162.09
Cash & Liquidity
Book Value per Share (MRQ)₹580.47₹100.81
Cash per Share (MRQ)₹194.34₹121.65
Operating Cash Flow (TTM) i₹7.50B₹12.73B
Levered Free Cash Flow (TTM) i₹6.99B₹9.28B
Dividends
Last 12-Month Dividend Yield i1.95%1.65%
Last 12-Month Dividend i₹38.00₹54.00

Valuation & Enterprise Metrics Analysis: Gland Pharma Ltd. vs GlaxoSmithKline Pharmaceuticals Ltd.

MetricGLAND (Apr 24, 2026)GLAXO (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i34.8641.55
Forward P/E i25.0336.46
PEG Ratio i0.582.44
Price to Sales (TTM) i4.8411.14
Price to Book (MRQ) i3.0924.80
Market Capitalization
Market Capitalization i₹295.80B₹422.67B
Enterprise Value i₹266.81B₹397.44B
Enterprise Value Metrics
Enterprise to Revenue i4.3710.46
Enterprise to EBITDA i18.8031.46
Risk & Other Metrics
Beta i0.410.10
Book Value per Share (MRQ) i₹580.47₹100.81

Financial Statements Comparison: Gland Pharma Ltd. vs GlaxoSmithKline Pharmaceuticals Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricGLAND (2025)GLAXO (2025)
Revenue/Sales i55.84B37.26B
Cost of Goods Sold i20.90B14.73B
COGS % of Revenue i37.4%39.5%
Gross Profit i34.93B22.53B
Gross Margin i62.6%60.5%
Research & Development i332.84MN/A
Operating Income (EBIT) i8.90B11.14B
Operating Margin i15.9%29.9%
EBITDA i14.76B12.55B
EBITDA Margin i26.4%33.7%
Pre-Tax Income i10.63B12.60B
Pre-Tax Income % of Revenue i19.0%33.8%
Income Tax i3.64B3.32B
Income Tax % of Revenue i6.5%8.9%
Net Income (Profit) i6.99B9.28B
Profit Margin i12.5%24.9%

Balance Sheet & Liquidity Metrics

MetricGLAND (2025)GLAXO (2025)
Cash & Equivalents i25.56B5.39B
Total Current Assets i67.83B34.10B
Total Current Assets % of Revenue i121.5%91.5%
Total Current Liabilities i15.65B19.05B
Total Current Liabilities % of Revenue i28.0%51.1%
Long-Term Debt i1.07B24.92M
Long-Term Debt % of Revenue i1.9%0.1%
Total Shareholders Equity i91.51B19.51B
Retained Earnings i71.57B10.59B
Retained Earnings % of Revenue i128.2%28.4%
Property, Plant & Equipment i3.59B2.70B

Cash Flow Statement Comparison

MetricGLAND (2025)GLAXO (2025)
Operating Cash Flow i7.50B12.73B
Operating Cash Flow % of Revenue i13.4%34.2%
Capital Expenditures i-3.84B-190.05M
Free Cash Flow i5.21B12.65B
FCF Margin i9.3%34.0%
Debt Repayment i-628.24MN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricGLANDGLAXO
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i164.76M169.41M
Float Shares i79.36M41.25M
% Held by Insiders i51.84%75.65%
% Held by Institutions i36.58%7.47%
% Held by Public i11.58%16.88%

Dividend Analysis & Yield Comparison: Gland Pharma Ltd. vs GlaxoSmithKline Pharmaceuticals Ltd.

MetricGLANDGLAXO
Last 12-Month Dividend i₹38.00₹54.00
Last 12-Month Dividend Yield i1.95%1.65%
3-Year Avg Annual Dividend i₹12.67₹59.33
3-Year Avg Dividend Yield i1.00%1.86%
3-Year Total Dividends i₹38.00₹178.00
Ex-Dividend DateAug 14, 2025May 30, 2025